Relebactam

Relebactam is a beta-lactamase inhibitor that is used in combination with imipenem and cilastatin to treat certain types of bacterial infections. It is marketed under the brand name Recarbrio by Merck & Co..

Mechanism of action[edit | edit source]

Relebactam works by inhibiting the action of beta-lactamase enzymes, which are produced by some bacteria to resist the effects of beta-lactam antibiotics. By blocking these enzymes, relebactam allows the antibiotics to work more effectively.

Uses[edit | edit source]

Relebactam is used in combination with imipenem and cilastatin to treat complicated urinary tract infections, complicated intra-abdominal infections, and hospital-acquired pneumonia.

Side effects[edit | edit source]

Common side effects of relebactam include nausea, diarrhea, and headache. Serious side effects may include allergic reactions, seizures, and Clostridium difficile infection.

History[edit | edit source]

Relebactam was approved for medical use in the United States in July 2019. It was developed by Merck & Co. as a means to combat antibiotic resistance.

See also[edit | edit source]

Relebactam Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.